title: Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.
abstract: The contribution of Th17 cells to the development of colitis is well described. The effector cytokines IL-17A and IL-17F have been proposed as potential therapeutic targets for the treatment of patients with inflammatory bowel disease. In a proof-of-concept study for the treatment of patients with Crohn's disease, secukinumab, a monoclonal antibody directed against IL-17A, was ineffective and associated with more adverse events than placebo. Wedebye Schmidt et al. propose that blockade of both IL-17A and IL-17F, rather than either cytokine alone, attenuates the development of colitis in a T-cell transfer model of experimental colitis. These findings suggest that combined blockade of IL-17A and IL-17F may be an effective strategy for the treatment of patients with inflammatory bowel disease.
authors.affiliation: University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology & Hepatology, MD, USA.
authors.forename: Leon P
authors.initials: LP
authors.lastname: McLean
authors.forename: Raymond K
authors.initials: RK
authors.lastname: Cross
authors.forename: Terez
authors.initials: T
authors.lastname: Shea-Donohue
mesh_terms: D000818:Animals; D003092:Colitis / Q000517:prevention & control*; D005260:Female; D007249:Inflammation / Q000517:prevention & control*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D007422:Intestines / Q000473:pathology*; D058504:Th17 Cells / Q000473:pathology*
chemical_list: D020381:Interleukin-17